We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Protein Levels Indicate Transplant Rejection

By LabMedica International staff writers
Posted on 30 Sep 2010
A simple, inexpensive blood test could soon help doctors halt organ rejection before it impairs transplanted hearts and kidneys.

Three easily measured proteins were identified that rise in the blood during acute rejection, in which a patient's immune system attacks his or her transplanted organ.

The new blood test will let doctors skip directly to drug dosing before the transplant is damaged. More...
As well as treating rejection early, doctors could use the test to reduce doses of immune-suppressing drugs for patients whose bodies are handling their transplanted organs well, thus reducing unnecessary drug side effects.

A Stanford University School of Medicine (Stanford, CA, USA) team identified the three proteins that indicate kidney and heart transplant rejection. The team's findings were published online on September 23, 2010, in PLoS-Computational Biology. The protein signals are now also being validated in liver- and lung-transplant recipients.

"In the past, we couldn't spot rejection episodes until they harmed the organ,” said Atul Butte, M.D., Ph.D., associate professor of medical informatics and of pediatrics at the Stanford University School of Medicine, and director of the Center for Pediatric Bioinformatics at Lucile Packard Children's Hospital (Stanford, CA, USA). "Our goal is to develop blood tests that will keep transplanted organs functioning so that patients can avoid a second transplant.”

Currently, an invasive, expensive, slow system is used to monitor transplants. Organ recipients receive functional monitoring of their new body parts. If organ function drops, doctors cut a tiny sample from the transplanted tissue to check for rejection, and then adjust the patient's immune-suppressing drugs accordingly.

Related Links:

Stanford University School of Medicine
Lucile Packard Children's Hospital




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.